|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alazawi W, Cunningham M, Dearden J and
Foster GR: Systematic review: Outcome of compensated cirrhosis due
to chronic hepatitis C infection. Aliment Pharmacol Ther.
32:344–355. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bertino G, Demma S, Ardiri A, Proiti M,
Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M,
Malaguarnera M and Di Carlo I: Hepatocellular carcinoma: Novel
molecular targets in carcinogenesis for future therapies. Biomed
Res Int. 2014:2036932014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Faivre S, Bouattour M and Raymond E: Novel
molecular therapies in hepatocellular carcinoma. Liver Int. 31
Suppl 1:S151–S160. 2011. View Article : Google Scholar
|
|
7
|
Liang XJ, Finkel T, Shen DW, Yin JJ,
Aszalos A and Gottesman MM: SIRT1 contributes in part to cisplatin
resistance in cancer cells by altering mitochondrial metabolism.
Mol Cancer Res. 6:1499–1506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Michan S and Sinclair D: Sirtuins in
mammals: Insights into their biological function. Biochem J.
404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dali-Youcef N, Lagouge M, Froelich S,
Koehl C, Schoonjans K and Auwerx J: Sirtuins: The ‘magnificent
seven’, function, metabolism and longevity. Ann Med. 39:335–345.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varotti G, Ramacciato G, Ercolani G, Grazi
GL, Vetrone G, Cescon M, Del Gaudio M, Ravaioli M, Ziparo V, Lauro
A and Pinna A: Comparison between the fifth and sixth editions of
the AJCC/UICC TNM staging systems for hepatocellular carcinoma:
Multicentric study on 393 cirrhotic resected patients. Eur J Surg
Oncol. 31:760–767. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carafa V, Rotili D, Forgione M, Cuomo F,
Serretiello E, Hailu GS, Jarho E, Lahtela-Kakkonen M, Mai A and
Altucci L: Sirtuin functions and modulation: From chemistry to the
clinic. Clin Epigenetics. 8:612016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kida Y and Goligorsky MS: Sirtuins, cell
senescence and vascular aging. Can J Cardiol. 32:634–641. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu W, Zuo Y, Feng Y and Zhang M: SIRT5
facilitates cancer cell growth and drug resistance in non-small
cell lung cancer. Tumour Biol. 35:10699–10705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iaquinta PJ and Lees JA: Life and death
decisions by the E2F transcription factors. Curr Opin Cell Biol.
19:649–657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Polager S and Ginsberg D: E2F – at the
crossroads of life and death. Trends Cell Biol. 18:528–535. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mori K, Uchida T, Fukumura M, Tamiya S,
Higurashi M, Sakai H, Ishikawa F and Shibanuma M: Linkage of E2F1
transcriptional network and cell proliferation with respiratory
chain activity in breast cancer cells. Cancer Sci. 107:963–971.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu M, Seto E and Zhang J: E2F1 enhances
glycolysis through suppressing Sirt6 transcription in cancer cells.
Oncotarget. 6:11252–11263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsantoulis PK and Gorgoulis VG:
Involvement of E2F transcription factor family in cancer. Eur J
Cancer. 41:2403–2414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Palaiologou M, Koskinas J, Karanikolas M,
Fatourou E and Tiniakos DG: E2F-1 is overexpressed and
pro-apoptotic in human hepatocellular carcinoma. Virchows Arch.
460:439–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gorgoulis VG, Zacharatos P, Mariatos G,
Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N,
Kittas C and Papavassiliou AG: Transcription factor E2F-1 acts as a
growth-promoting factor and is associated with adverse prognosis in
non-small cell lung carcinomas. J Pathol. 198:142–156. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu Y, Cheng Y, Song Y, Zhang Z, Deng M,
Wang C, Zheng G and He Z: MicroRNA-493 suppresses tumor growth,
invasion and metastasis of lung cancer by regulating E2F1. PLoS
One. 9:e1026022014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hao C, Zhu PX, Yang X, Han ZP, Jiang JH,
Zong C, Zhang XG, Liu WT, Zhao QD, Fan TT, et al: Overexpression of
SIRT1 promotes metastasis through epithelial-mesenchymal transition
in hepatocellular carcinoma. BMC Cancer. 14:9782014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mima K, Hayashi H, Kuroki H, Nakagawa S,
Okabe H, Chikamoto A, Watanabe M, Beppu T and Baba H:
Epithelial-mesenchymal transition expression profiles as a
prognostic factor for disease-free survival in hepatocellular
carcinoma: Clinical significance of transforming growth factor-β
signaling. Oncol Lett. 5:149–154. 2013.PubMed/NCBI
|
|
25
|
Li YM, Xu SC, Li J, Han KQ, Pi HF, Zheng
L, Zuo GH, Huang XB, Li HY, Zhao HZ, et al: Epithelial-mesenchymal
transition markers expressed in circulating tumor cells in
hepatocellular carcinoma patients with different stages of disease.
Cell Death Dis. 4:e8312013. View Article : Google Scholar : PubMed/NCBI
|
